Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults

NCT05361434 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT05361434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05361434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
September 26, 2022
Completion date
October 20, 2025
Enrollment
311 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma